Why DGX Matters Now
Quest Diagnostics Incorporated is trading near its historical overvaluation band. Current yield 1.7% vs historical max 2.6% (63% of maximum). 14 consecutive years without a dividend cut. Conservative payout ratio of 36%.
Weiss Valuation: Where Does DGX Stand Today?
At 1.67%, DGX's current yield is near the bottom of its 10-year historical range (1.54%–2.64%). By the Weiss method this indicates that the market is pricing the stock for optimism — investors are paying a premium relative to the income the stock generates. The historical median yield is 2.07%, suggesting the stock is trading well above fair value.
The undervalued price threshold — the level at which DGX historically becomes an attractive buy — currently sits at $137.37. The overvalued threshold, above which the stock is historically expensive, is $186.48. The current price of $195.21 places the stock above the overvalued band — a signal to review position sizing.
Dividend Quality Assessment
Quest Diagnostics Incorporated scores 80/100 on DividendVisual's quality scale — an Excellent rating, placing it among the most reliable dividend payers in our universe. Key metrics: a 36% payout ratio, the dividend consumes 40% of free cash flow, growing at 7.3% annually over the past 5 years.
Quest Diagnostics Incorporated has grown its dividend for 14 consecutive years, demonstrating a decade of reliable income growth.
The current payout ratio is 36% — a conservative level that leaves significant room for future increases and protects the dividend in a downturn.
Peer Context: Is DGX the Best Setup?
ABT currently offers a higher yield than DGX, but yield alone is not the decision. Compare quality score and payout coverage to decide whether the extra income is compensation for higher risk.
10-Year Yield History
Over the past decade, Quest Diagnostics Incorporated's dividend yield has ranged from a low of 1.54% (when the stock was most expensive relative to its dividend) to a high of 2.64% (when it was most attractively priced). The historical median yield — a reasonable proxy for fair value — is 2.07%.
Investors who consistently bought DGX near its historical yield maximum and held for 3–5 years have, historically, earned both above-average income and above-average capital appreciation as the yield mean-reverted toward the median. This is the core logic of yield-based valuation: price and yield are inversely related, so buying high yield means buying low price.
Income Projection: What DGX Could Generate
A $10,000 investment at the current price and yield would generate approximately $167 in year-one income. With dividends reinvested and a 7.3% annual growth rate maintained, that same investment would produce roughly $435 per year in income by year 10 — a yield on cost of 4.3%.
These projections assume no share price appreciation — only the compounding effect of reinvested dividends at a constant price. In practice, share price changes will affect the total return. The projection is intended to illustrate the power of dividend reinvestment over time, not to predict a specific outcome.
Key Risks to Consider
Quest Diagnostics Incorporated's dividend appears well-supported by current earnings and cash flow. No material red flags are flagged by the quality model, though macro risks (rising rates, sector disruption) always apply.
For healthcare dividend stocks, patent cycles, reimbursement pressure, product pipelines, and litigation can matter as much as current payout ratios. A safe-looking dividend still needs durable earnings power behind it.
Beyond company-specific factors, all dividend stocks carry interest rate risk: when rates rise, income investors have alternatives, and dividend stock valuations tend to compress. Quest Diagnostics Incorporated's position in the Healthcare sectorshould be evaluated in the context of your portfolio's overall rate sensitivity.
What to Watch Next
- Yield moving toward 2.64% would strengthen the undervaluation signal; yield falling toward 2.07% would indicate mean reversion.
- Payout ratio staying below 60% would support dividend flexibility.
- Free-cash-flow payout near 40% should be monitored for deterioration.
- Dividend growth above 7.3% would confirm the income-compounding case; a slowdown would reduce the appeal.
Bottom Line
At current prices, Quest Diagnostics Incorporated is trading at historically elevated valuations relative to its dividend yield. Income investors may find better entry points elsewhere in the dividend universe. Existing holders have no urgent reason to sell — the dividend remains intact — but initiating a new position here means accepting below-median long-term income returns relative to cost.